Introduction: National transplant registries routinely focus on centre-specific patient and graft survival rates following renal transplantation. However other outcomes such as graft function (as measured by eGFR), haemoglobin and blood pressure are also important quality of care indicators. Methods: Renal transplant activity, incident graft survival data and donor information were obtained from NHS Blood and Transplant. Laboratory and clinical variables and prevalent survival data were obtained from the UK Renal Registry. Data were analysed separately for prevalent and one year post-transplant patients. Results: The main increase in transplant activity in 2012 was the use of donors after circulatory death. The death-censored graft failure rate was similar to previous years at 2.2% and the transplant patient death rates remained stable at 2.3 per 100 patient years. There was centre variation in outcomes including eGFR and haemoglobin in prevalent and 1 year posttransplant patients. Analysis of prevalent transplants by chronic kidney disease stage showed 13.7% with an eGFR ,30 ml/min/1.73 m 2 and 1.7% with an eGFR ,15 ml/min/ 1.73 m 2 . Of those with CKD stage 5T, 33% had haemoglobin concentrations ,100 g/L, 27.6% phosphate concentrations 1.7 mmol/L and 20.5% adjusted calcium concentrations 2.5 mmol/L. Infection (23%) and malignancy (20%) remained amongst the commonest causes of death in patients with a functioning renal transplant. Conclusions: Significant variations in clinical outcomes (unadjusted for patient specific variables) amongst kidney transplant recipients continued to exist in the UK and may reflect differences in healthcare delivery between renal centres.
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Introduction
This chapter includes independent analyses regarding renal transplant activity and survival data from the UK Transplant Registry, held by the Organ Donation and Transplantation Directorate (ODT) of NHS Blood and Transplant (NHSBT). The UK Renal Registry (UKRR) has performed additional analyses of renal transplant recipient follow-up data examining demographics, clinical and biochemical variables. NHSBT records all the information regarding the episode of transplantation (donor and recipient details) and the UKRR holds additional information on key clinical and biochemical variables in renal transplant recipients. The co-operation between these two organisations results in a comprehensive database describing the clinical care delivered to renal transplant patients within the UK. This further allows for the comparison of key outcomes between centres and provides insight into the processes involved in the care of such patients in the UK.
This chapter is divided into six sections: (1) transplant activity, waiting list and survival data; (2) transplant demographics; (3) clinical and laboratory outcomes; (4) analysis of prevalent patients by chronic kidney disease (CKD) stage; (5) eGFR slope analysis; and (6) causes of death in transplant recipients. Methodology, results and conclusions of these analyses are discussed in detail for all six sections separately.
The UK Renal Registry methodology is described elsewhere [1] . The UKRR collects quarterly clinical data via an electronic data extraction process from hospital based renal IT systems on all patients receiving renal replacement therapy. Throughout the chapter, the number preceding the centre name in each figure indicates the percentage of missing data for that centre for that variable.
Unless otherwise specified, prevalent transplant patients were defined as patients with a functioning renal transplant on the 31st December 2012.
Transplant activity, waiting list activity and survival data Introduction NHSBT prospectively collects donor and recipient data around the episode of transplantation. They also request that transplant centres provide an annual paper based data return on the status of the recipient's graft function.
This enables ODT to generate comprehensive analyses of renal transplant activity and graft survival statistics.
NHSBT attributes a patient to the centre that performed the transplant operation irrespective of where the patient was cared for before or after the procedure and hence only reports on transplant centre performance.
Methods
In 2012, there were 23 UK adult renal transplant centres, 19 in England, 2 in Scotland and 1 each in Northern Ireland and Wales.
Comprehensive information from 1999 onwards concerning the number of patients on the transplant waiting list, the number of transplants performed, the number of deceased kidney donors (donor after brainstem death and donor after circulatory death), living kidney donors, patient survival and graft survival is available on the NHSBT website (http://www.organdonation.nhs.uk/ukt/ statistics/statistics.asp).
Results
During 2012, 2,901 kidney or kidney plus other organ transplants were performed. The absolute number of living kidney donors showed a 1% rise in 2012 representing 35.6% of all transplants performed whilst donor after circulatory death transplants continued to increase and comprised 24.4% of all kidney transplants performed. A small rise in the number of transplants from donors after brainstem death was also noted in 2012 partially reversing the small decline noted in 2011 (table 3.1).
There were small differences in one and five year riskadjusted patient and graft survival rates amongst UK renal transplant centres (table 3. 2). These graft survival rates include grafts with primary non-function (which are excluded from analysis by some countries). Using data from the UKRR on prevalent renal only transplant patients on 1st January 2012, the death rate during 2012 was 2.3/100 patient years (CI 2.1-2.5) when censored for return to dialysis and 2.4/100 patient years (CI 2.2-2.6) without censoring for dialysis. These death rates are similar to those observed over the last few years.
During 2012, 2.2% of prevalent transplant patients experienced graft failure (excluding death as a cause of graft failure) maintaining the fall in graft failure rates noted over the last couple of years. Whilst it might be premature to assume that graft failure rates are falling in the UK the 0.5% fall noted in the last five years is certainly encouraging.
Conclusions
In 2012, the increased number of kidney transplants performed was mostly due to the growing use of organs from donors after circulatory death. The graft failure rate of 2.2% per annum and patient death rate of 2.3 per 100 patient years were similar to those noted in 2011.
Transplant demographics

Introduction
Since 2008, all UK renal centres have established electronic linkage to the UKRR or Scottish Renal Registry, giving the UKRR complete coverage of individual patient level data across the UK.
The following sections need to be interpreted in the context of variable repatriation policies; some transplant centres continue to follow up and report on all patients they transplant, whereas others refer patients back to non-transplant centres for most or all ongoing posttransplant care. Some transplant centres only refer back patients when their graft is failing. The time B QEH  88  96  83  89  96  99  88  96  Belfast  93  95  91  92  94  100  92  93  Bristol  94  96  84  85  98  99  95  98  Camb  92  97  85  90  99  99  96  100  Cardff  96  98  85  88  95  98  88  96  Covnt  88  94  89  91  96  100  88  96  Edin  90  95  83  85  95  98  91  97  Glasgw  93  97  84  84 Newc  93  95  83  89  99  99  93  98  Nottm  94  95  80  86  95  99  91  94  Oxford  94  96  89  87  96  96  98  94  Plymth  88  97  86  89  95  99  88  93  Ports  95  95  80  88  94  99  82  91  Sheff  91  98  81  92  98  100  89  100  All centres  93  96  84  88  96  96  96  96 post-transplantation that a patient is referred back to their local centre varies between transplant centres. The UKRR is able to detect duplicate patients (being reported from both transplant and referring centres) and in such situations care is attributed to the referring centre. This process may result in some discrepancies in transplant numbers particularly in Oxford/Reading and Clywd/ Liverpool RI.
Methods
Four centres (Bangor, Colchester, Liverpool Aintree and Wirral) did not have any transplant patients and were excluded from some of the analyses. Their dialysis patients were included in the relevant dialysis population denominators.
For the analysis of primary renal diagnosis (PRD) in transplant recipients, a few centres were excluded from some of the take-on years because of concerns relating to the reliability of PRD coding (with these centres submitting a high percentage of uncertain or missing aetiology codes).
Information on patient demographics (age, gender, ethnicity and PRD) for patients in a given renal centre was obtained from UKRR patient registration data fields. Individual patients were assigned to the centre that returned data for them during 2012. The prevalence of transplant patients in areas covered by individual primary care trusts (PCT) or Health Boards/Social Care Areas (HB) was estimated based on the post code of the registered address for patients on renal replacement therapy (RRT). Data on ethnic origin, supplied as Patient Administration System (PAS) codes, were retrieved from fields within renal centre IT systems. For the purpose of this analysis, patients were grouped into Whites, South Asians, Blacks, Others and Unknown. The details of ethnicity regrouping into the above categories are provided in appendix H: Coding http://www.renalreg.com.
Results and discussion
Prevalent transplant numbers across the UK are described in table 3.3.
The prevalence of renal transplant recipients in each PCT/HB in England, Northern Ireland (Health and Social Care Trust Areas), Scotland (Health Boards) and Wales (Local Health Boards) and the proportion of prevalent patients according to modality in the renal centres across the UK is described in tables 3.4 and 3.5 respectively. After standardisation for age and gender, unexplained variability was evident in the prevalence of renal transplant recipients, with some areas having higher than the predicted number of prevalent transplant patients per million population and others lower. There are a number of potential explanations for these inconsistencies, including geographical differences in access to renal transplantation in the UK. This has previously been analysed in detail by the UKRR [2] and is currently the focus of a large national study (access to Transplant and Transplant Outcome Measures (ATTOM)).
The proportion of prevalent RRT patients with a transplant relative to the number on dialysis has been relatively stable over the last decade.
Age and gender
The gender ratio amongst incident and prevalent transplant patients has remained stable for at least the last ten years (table 3.6, figure 3.1). Note absolute patient numbers differ from those published in previous reports as a result of additional data validation and reallocation of patients. The average age of incident transplant patients has steadily increased during the same time period. There has also been a gradual increase in the average age of prevalent transplant patients, which could reflect the increasing age at which patients are transplanted and/or improved survival after renal transplantation over the last few years. The prevalent transplant patient workload across the UK increased to 27,621 patients at the end of 2012. The continued expansion of this patient group means there is a need for careful planning by renal centres for future service provision and resource allocation.
Primary renal diagnosis
The primary renal diagnosis of patients receiving kidney transplants in the UK has remained relatively stable over the last five years (table 3.7).
Ethnicity
It was difficult to compare the proportion of patients within each ethnic group receiving a transplant to those commencing dialysis from the same group because data on ethnicity were missing in a considerable number of Pruthi/Casula/MacPhee 
Clinical and laboratory outcomes
Introduction There continued to be marked variation in the completeness of data (tables 3.9a, 3.9b) reported by each renal centre, particularly for blood pressure. Better data records (or possibly better extraction of data held within renal IT systems) would facilitate more meaningful comparisons between centres and help to determine the causes of inter-centre differences in outcomes. For this reason, along with differences in repatriation policies of prevalent transplant patients between centres as highlighted previously, caution needs to be exercised when comparing centre performance.
The 71 renal centres in the UK comprise 52 centres in England, five in Wales, five in Northern Ireland and nine in Scotland. Four centres (Bangor, Colchester, Liverpool Aintree and Wirral) were reported as having no transplanted patients and were therefore excluded. After Pruthi/Casula/MacPhee Outcomes in UK renal transplant recipients in 2012 Blank cells denote no patients on that modality exclusion of these four centres, prevalent patient data from 67 renal centres across the UK were analysed.
For the one year post-transplant analyses, in which patients were assigned to the centre that performed their transplant, all 23 transplant centres across the UK were included in the analysis for the first time this year.
Methods
Data for key laboratory variables are reported for all prevalent patients with valid data returns for a given renal centre (both transplanting and non-transplanting centres) and for one year post-transplant results for patients transplanted 2005-2011, with patients attributed to the transplant centre that performed the procedure.
Time since transplantation may have a significant effect on key biochemical and clinical variables and this is likely to be independent of a centre's clinical practices. Therefore, inter-centre comparison of data on prevalent transplant patients is open to bias. To minimise bias relating to fluctuations in biochemical and clinical parameters occurring in the initial post-transplant period, one year post-transplantation outcomes are also reported. It is presumed that patient selection policies and local clinical practices are more likely to be relevant in influencing outcomes 12 months post-transplant and therefore comparison of outcomes between centres is more robust. However, even the 12 months post-transplant comparisons could be biased by the fact that in some centres, repatriation of patients only occurs if the graft is failing whereas in others it only occurs if the graft function is stable.
Centres with ,20 patients or ,50% data completeness have been excluded from the figures. Scottish centres were also excluded from blood pressure analyses as data not provided.
Prevalent patient data
Biochemical and clinical data for patients with a functioning transplant followed in either a transplanting or non-transplanting centre were included in the analyses. The cohort consisted of prevalent patients as on 31st December 2012. Patients were considered as having a functioning transplant if 'transplant' was listed as the last mode of RRT in the last quarter of 2012. Patients were assigned to the renal centre that sent the data to the UKRR but some patients will have received care in more than one centre. If data for the same transplant patient were received from both the transplant centre and non-transplant centre, care was allocated to the non-transplant centre. Patients with a functioning transplant of less than three months duration were excluded from analyses. For haemoglobin, estimated glomerular filtration rate (eGFR), corrected calcium, phosphate and blood pressure (BP), the latest value in quarter 3 or quarter 4 of 2012 was used.
Estimated glomerular filtration rate (eGFR)
For the purpose of eGFR calculation, the original 4-variable MDRD formula was used (with a constant of 186) to calculate eGFR from the serum creatinine concentration as reported by the centre (unless otherwise stated). A wide variety of creatinine assays are in use in clinical biochemistry laboratories in the UK, and it is not possible to ensure that all measurements of creatinine concentration collected by the UKRR are harmonised. Although many laboratories are now reporting assay results that have been aligned to the isotope dilution-mass spectrometry standard (which would necessitate use of the modified MDRD formula), this was not the case at the end of 2012. Patients with valid serum creatinine results but no ethnicity data were classed as White for the purpose of the eGFR calculation.
One year post-transplant data
Patients who received a renal transplant between 1st January 2005 and 31st December 2011 were assigned according to the renal centre in which they were transplanted. In a small number of instances, the first documented evidence of transplantation in a patient's record is from a timeline entry in data returned from a non-transplant centre, in these instances the patient was reassigned to the nearest transplant centre (table 3.10).
Patients who had died or experienced graft failure within 12 months of transplantation were excluded from the analyses. Patients with more than one transplant during 2005-2011 were included as separate episodes provided each of the transplants functioned for a year.
For each patient, the most recent laboratory or blood pressure result for the relevant 4th/5th quarter (10-15 months) after renal transplantation was taken to be representative of the one year post-transplant outcome. Again, for the purpose of the eGFR Leeds  810  97  85  97  97  49  Leic  930  96  88  96  96  56  Liv RI  794  89  57  85  87  68  M RI  1,080  99  43  98  98  59  Middlbr  423  95  31  92  91  12  Newc  603  98  69  98  98  45  Norwch  232  98  93  94  94  24  Nottm  535  100  55  97  92  78  Oxford  978  99  55  98  98  29  Plymth  280  97  41  95  94  42  Ports  784  94  35  92  88  17  Prestn  466  98  41  95  92  2  Redng  326  98  76  97  80  40  Salford  384  91  76  94  94  82  Sheff  627  99  41  99  99  25  Shrew  116  91  67  77  78  7  Stevng  216  96  70  91  88  54  Sthend  79  99  29  96  96  13  Stoke  309  98  98  98  98  39  Sund  194  100  85  100  100  88  Truro  191  98  60  96  96  57  Wolve  146  97  60  94  82  37  York  221  85  55  98  95  21 Outcomes in UK renal transplant recipients in 2012
Nephron Clin Pract 2013;125:55-80 calculation patients with valid serum creatinine results but missing ethnicity data were classed as White.
Results and discussion
Post-transplant eGFR in prevalent transplant patients
When interpreting eGFR post-transplantation, it is important to remember that estimated GFR formulae only have a modest predictive performance in the transplant population [4] . Median eGFR in each centre and percentage of patients with eGFR ,30 ml/min/1.73 m 2 are shown in figures 3.2 and 3.3. The median eGFR was 51.3 ml/min/1.73 m 2 , with 13.7% of prevalent transplant recipients having an eGFR ,30 ml/min/1.73 m 2 . Table 3 .11 summarises the proportion of transplant patients with an eGFR ,30 ml/min/1.73 m 2 by centre. Whilst local repatriation policies on timing of transfer of care for patients with failing transplants from transplant centres to referring centres might explain some of the differences, it is notable that both transplanting and non-transplanting centres feature at both ends of the scale. The accuracy of the 4-variable MDRD equation in estimating GFR 60 ml/min/1.73 m 2 is questionable [5] , therefore a figure describing this is not included in this chapter. There continued to be variation between centres; these data show over-dispersion with 17 centres falling outside the 95% CI of which eight centres were outside the 99.9% CI. Four centres (Newry, London St Georges, London West, Nottingham) fell outside the lower 99.9% CI suggesting a lower than expected proportion of patients with eGFR ,30 ml/min/1.73 m 2 . Liverpool RI, Portsmouth, Manchester RI and London Barts fell outside the upper 99.9% CI suggesting a higher than Graft function at one year post-transplantation may predict subsequent long term graft outcome [6] . 
Haemoglobin in prevalent transplant patients
Transplant patients have previously fallen under the remit of the UK Renal Association Complications of Chronic Kidney Disease (CKD) guidelines. Updated guidelines regarding the management of anaemia in CKD were published by the association in November 2010 [7] which have now been adopted for this report. These guidelines recommend achieving a population distribution centred on a mean of 11 g/dl with a range of 10-12 g/dl [8] (equivalent to 110 g/L, range 100-120 g/L). However, many transplant patients with good transplant function will have haemoglobin concentrations .120 g/L without the use of erythopoiesis stimulating agents, and so it is inappropriate to audit performance using the higher limit.
A number of factors including comorbidity, immunosuppressive medication, graft function, ACE inhibitor use, erythropoietin (EPO) use, intravenous or oral iron use, as well as centre practices and protocols for management of anaemia, affect haemoglobin concentrations in transplant patients. Most of these data are not collected by the UKRR and therefore caution must be used when interpreting analyses of haemoglobin attainment. Figures 3.7a and  3 .7b report centre results stratified according to graft function as estimated by eGFR. The percentage of prevalent transplant patients achieving Hb 100 g/L in each centre, stratified by eGFR, is displayed in figures 3.8a and 3.8b. Figure 3 .9 describes the percentage of prevalent patients by centre with haemoglobin ,100 g/L as a funnel plot enabling more reliable comparison of outcomes between centres across the UK. With 65 centres included and a normal distribution, 3-4 centres would be expected to fall between the 95%-99.9% CI (1 in 20) and no centres should fall outside the 99.9% CI purely as a chance event.
One centre (London Barts) fell outside the upper 99.9% CI and three further centres (London Royal Free, Norwich and Oxford) fell outside the upper 95% CI indicating a higher than predicted proportion of transplant patients not achieving the haemoglobin target. Six centres fell outside the lower 99.9% CI, indicating they performed better than expected with fewer than predicted patients having a haemoglobin ,100 g/L.
Blood pressure in prevalent transplant patients
In the absence of controlled trial data, the opinion based recommendation of the UK Renal Association (RA) published in the 2010 guideline for the care of kidney transplant recipients is that 'Blood pressure should be <130/80 mmHg (or <125/75 mmHg if proteinuria)' [9] . This blood pressure target is the same as that used in previous annual reports [10] .
As indicated in table 3.9a, completeness for blood pressure data returns was variable and only centres with .50% data returns were included for consideration. Despite this restriction, caution needs to be exercised in interpretation of these results because of the volume of missing data and potential bias, (e.g. a centre may be more likely to record and report blood pressure data electronically in patients with poor BP control). 
Introduction
Approximately 2.2% of prevalent transplant patients returned to dialysis in 2012, a similar percentage to that seen over the last few years. Amongst patients with native chronic kidney disease, late presentation is associated with poor outcomes, largely attributable to lack of specialist management of anaemia, acidosis, hyperphosphataemia and to inadequate advance preparation for dialysis. Transplant recipients on the other hand, are almost always followed up regularly in specialist transplant or renal clinics and it would be reasonable to expect patients with 
Methods
The transplant cohort consisted of prevalent transplant recipients as on 31st December 2012 (N = 25,166) and were classified according to the KDIGO staging criteria with the suffix of 'T' to represent their transplant status. Patients with missing ethnicity information were classified as White for the purpose of calculating eGFR. Prevalent dialysis patients, except those who commenced dialysis in 2012, comprised the comparison dialysis cohort (N = 21,242) including 2,467 peritoneal dialysis patients. Only patients on peritoneal dialysis were considered when examining differences in serum phosphate between transplant recipients and dialysis patients. For both the transplant and dialysis cohorts, the analysis used the most recent available value from the last two quarters of the 2012 laboratory data. Scottish centres were excluded from blood pressure, calcium, cholesterol and PTH analyses as corresponding data was not provided. Table 3 .12 shows that 13.7% of the prevalent transplant population (3,442 patients), had moderate to advanced renal impairment of eGFR ,30 ml/min/ 1.73 m 2 . The table also demonstrates that patients with failing grafts achieved UK Renal Association standards for some key biochemical and clinical outcome variables less often than dialysis patients. This substantial group of patients represents a considerable challenge, as resources need to be channelled to improve key outcome variables and achieve a safe and timely modality switch to another form of renal replacement therapy.
Results and discussion
eGFR slope analysis
Introduction
The gradient of deterioration in eGFR (slope) may predict patients likely to have early graft failure. The eGFR slope and its relationship to specific patient characteristics are presented here.
Methods
All UK patients aged 18 years receiving a renal transplant between 1st January 2001 and 31st December 2010, were considered for inclusion. A minimum duration of 18 months graft function was required and three or more creatinine measurements from the second year of graft function onwards were used to plot eGFR slope. If a transplant failed but there were at least three creatinine measurements between 18 months post-transplant and graft failure, the patient was included but no creatinine measurements after the quarter preceding the recorded date of transplant failure were analysed.
Slopes were calculated using linear regression, assuming linearity, and the effect of age, ethnicity, gender, diabetes, donor type, year of transplant and current transplant status were analysed. P values were calculated using the Kruskal-Wallis test. eGFR was calculated using the CKD-EPI equation and results expressed as ml/min/1.73 m 2 /year. The CKD-EPI equation was used in preference to the MDRD formula as it is thought to have a greater degree of accuracy at higher levels of eGFR [11] .
Results and discussion
The study cohort consisted of 14,783 patients. The median GFR slope was −0.53 ml/min/1.73 m 2 /year ( /year) compared to non-diabetic patients (−0.45 ml/min/1.73 m 2 /year). The slope was steeper in younger recipients, possibly reflecting increased risk of immunological damage. As might be expected, the steepest slope was in patients where the transplant subsequently failed. This analysis has assumed linearity of progression of fall in GFR and further work is underway to characterise the patterns of progression more precisely.
The findings in this study differ slightly from previous UKRR work exploring eGFR changes in transplant recipients [14] . This identified that male donor to female recipient transplantation, younger recipients, diabetes, white ethnicity, and human leukocyte antigen (HLA) mismatch were associated with faster decline in eGFR. These differences may be explained by patients with eGFR .60 ml/min/1.73 m 2 at one year post-transplantation being excluded and the more complex multivariable model used in the previous work. Udayaraj and colleagues [14] also adjusted for factors such as HLA mismatch and donor age, which were not available for the patients studied in this chapter. Introduction Differences in causes of death between dialysis and transplant patients may be expected due to selection for transplantation and use of immunosuppression. Chapter 8 includes a more detailed discussion on causes of death in dialysis patients.
Methods
The cause of death is sent by renal centres as an ERA-EDTA registry code. These have been grouped into the following categories: cardiac disease, cerebrovascular disease, infection, malignancy, treatment withdrawal, other and uncertain.
Some centres have high data returns to the UKRR regarding cause of death, whilst others return no information. Provision of this information is not mandatory.
Analysis of prevalent patients included all those aged over 18 years and receiving RRT on 31st December 2012.
Results and discussion Tables 3.14, 3.15 and figure 3.11 show the differences in the causes of death between prevalent dialysis and transplant patients. Death due to cardiovascular disease was less common in transplanted patients than in dialysis patients, perhaps reflecting the cardiovascular screening undertaken during transplant work-up; transplant recipients are a pre-selected lower risk group of patients. The leading causes of death amongst transplant patients were infection (23%), other (23%) and malignancy (20%). There has been a reduction over time in the proportion of deaths in transplant patients attributed to cardiovascular or stroke disease (43% in 2003 compared Pruthi/Casula/MacPhee Cardiac disease  647  22  575  22  72  18  Cerebrovascular disease  135  5  118  5  17  4  Infection  532  18  437  17  95  23  Malignancy  292  10  208  8  84  20  Treatment withdrawal  511  17  498  19  13  3  Other  624  21  528  20  96  23  Uncertain  245  8  212  8  33  8  Total  2, Conflicts of interest: Dr I MacPhee has received research funding and speaker honoraria from Astellas.
